<DOC>
	<DOCNO>NCT02002221</DOCNO>
	<brief_summary>The purpose study assess efficacy safety vildagliptin 50 mg bid add-on therapy improve overall glycemic control patient T2DM inadequately control insulin , without concomitant metformin treatment . It agree PMDA conduct postmarketing clinical trial collect efficacy safety data vildagliptin especially Japanese patient iwas use top insulin .</brief_summary>
	<brief_title>Study Efficacy Safety Vildagliptin add-on Insulin Therapy T2DM Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Confirmed diagnosis T2DM standard criterion . HbA1c ≥ 7.0 ≤ 10 % Visit 1 . Age : ≥ 20 &lt; 75 year old Visit 1 . BMI ≥ 20 ≤ 35 kg/m2 Visit 1 . FPG ≥ 270 mg/dL ( ≥15 mmol/L ) Visit 1 . Type 1 diabetes , monogenic diabetes , diabetes result pancreatic injury , secondary form diabetes . Significant heart diseases Hepatic disorder Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Diabetes Mellitus ( DM ) ,</keyword>
	<keyword>diabetes ,</keyword>
	<keyword>noninsulin-dependent diabetes mellitus ( NIDDM ) ,</keyword>
	<keyword>adult-onset diabetes ,</keyword>
	<keyword>high blood sugar ,</keyword>
	<keyword>T2DM</keyword>
</DOC>